Australian (ASX) Stock Market Forum

TLX - Telix Pharmaceuticals

Jump to new
The acquisition looks good however there is always risk.
Happy to hold. Looking forward to future announcements. Fairly confident and will keep holding.
 
Knobby22 said:
The company does appear to be focused and proactive.
Click to expand...
AGM today and well received .. up 2-3 per cent , now $12.58

excerpt from M.D.s speech

"Most relevant to today’s meeting, I will now elucidate the three areas of major focus in our corporate development and deal making. This strategy is highly evident in the deals that have been conducted using a combination of our placement capacity and cash, to the extent that we are able to spare it.

"The first is – as I have repeated several times – supply chain and manufacturing. Radiopharmaceuticals are a highly specialised area of pharma. There is no magic isotope store in the sky. These products have short shelf-lives. Supply chains are enormously complicated. Global reach is vital for product success. Failure to invest in this kind of infrastructure means – ultimately – failure to commercially grow the business. A startup company can be aspirational in its commercial strategy. A new commercial organisation tends to be more defensive. Telix is now at the stage where we need to assertively develop capacity to enable growth. Mostly, however, it’s a “buy vs build” decision – and we need, quite frankly, to do both. This philosophy underpins the acquisition of ARTMS and IsoTherapeutics Group.

"The second pillar is to continue to look at assets that round out our key disease focus areas. We are particularly focused on urology, central nervous system oncology or “neuro-oncology” and musculoskeletal oncology. We are building commercial capabilities that can focus on these unique customers and meet the needs of their patients. Therefore, building out a long-term portfolio of diagnostic, therapeutic and interventional assets that can deliver against those specific areas of clinical focus is highly appealing to Telix. This philosophy underpins the acquisition of QSAM Biosciences.

"Finally, we see rapid growth in our current and near-term commercial products. By the end of 2024, we expect to have multiple commercial products and considerably expanded territory coverage. As part of growing our revenue streams and maintaining our competitive edge, Telix will invest in products, technologies and service enhancements that enable us to expand our indications for use, reach new customers and deliver new clinical differentiation. This philosophy underpins the acquisition of Lightpoint and Dedicaid – technology platforms that are immediately additive to Illuccix® and will, over time, add enhancement to almost the entirety of Telix’s platform – if not all of it.
 
ATH , and aiming higher ? .. $13.61

Screenshot_20240418-144829_CommSec.jpg
 
As @Dona Ferentes mentioned, ATH (all-time high :) ) has increased.
It is an outstanding stock, but because I bought it at a very low price and sold out with a sufficient markup, my psychological barrier deters me from returning to this stock . Who knows how much I will regret it when it becomes a CSL 2 in a year
However, there will be a likely depression once the escrow shares are released - giving a momentary supply of stocks

@debtfree - one of four CY 2024 tips for me


1713964083570.png
 

Attachments

  • 1716041416697.png
    1716041416697.png
    140 KB · Views: 3
Miner said:
TLX is the only tip out of four that looks good.
The IPO in the USA will add significant value as well.

Financial performance and acquisition (except the price of $11.51 offered was unfair to current holders) are very positive.


View attachment 177154





View attachment 177152
Click to expand...
Thought the following was interesting as it provides a bit of blue sky.

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer • CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibodybased targeted alpha therapy for prostate cancer. • Establishes proof-of-concept for Telix’s proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets. • Initial results demonstrate rapid elimination from blood circulation compared to standard antibodies and hepatic (liver) clearance – both highly desirable characteristics for use with alpha emitting agents. • Successful completion of mass dose escalation study establishes a baseline dosing schedule for future studies of TLX592 using actinium-225. • Data is supportive of advancement to a therapeutic Phase I/II study in H2 2024.
 
Mitsubishi UFJ Financial Group has bought over 15% of the company which is interesting.
 
Dona Ferentes said:
ATH , and aiming higher ? .. $13.61
Click to expand...
and a robust 10 per cent up, to $17.40

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
• TLX591 is an investigational anti-PSMA radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.
• Reported median radiographic progression-free survival (rPFS) is 8.8 months.
• Builds on prior data from the ProstACT SELECT trial, demonstrating favourable safety profile and biodistribution
 
Dona Ferentes said:
and a robust 10 per cent up, to $17.40

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
• TLX591 is an investigational anti-PSMA radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.
• Reported median radiographic progression-free survival (rPFS) is 8.8 months.
• Builds on prior data from the ProstACT SELECT trial, demonstrating favourable safety profile and biodistribution
Click to expand...
Finished at $18.15!
 
Miner said:
The IPO in the USA will add significant value as well.
Click to expand...
looking good:
.
Telix Pharmaceuticals may raise more that its intended $300.6m in gross proceeds from its US initial public offer after its share price jumped 4.4 per cent to $18.67 in early ASX trading today.

Telix is offering 17 million American Depositary Shares via the IPO, with the final price per share to be determined on the basis of its last ASX trading price before the IPO through negotiations with its underwriters Jefferies, Morgan Stanley, Truist Securities and William Blair.

In the prospectus, the price was assumed at $US11.87 per ADS based on Telix's closing share price of $17.80 on 04 June.
 
Telix Pharmaceuticals shares will resume trading this morning after electing to withdraw its proposed initial public offering in the US.

Given the proposed Nasdaq listing – announced in January, was not predicated on the need to raise capital, Telix's management and board decided not to move forward with the transaction at the terms provided "under current market conditions".

"The company did not feel that the proposed discounts were aligned with its duty to its existing shareholders," it told investors on Friday. Telix said it has achieved a number of commercially significant milestones, including positive therapeutic pipeline data readouts, several successful strategic acquisitions and the completion of two further product approval submissions to the US Food and Drug Administration
 
Miner said:
Once again, TLX is running a stellar show for tomorrow's CSL. Readmittance to Nasdaq is another future milestone to happen in FY 25 (I hope)

Massive performance upgrade

View attachment 179171View attachment 179172
Click to expand...
The cancelling of the USA listing which was supposedly needed to obtain funds to speed up the clinical trials was cancelled yet the price keeps increasing.

My take is that we, the Australian shareholders are better off because:
1. We don't get diluted
2. We don't have to wear the costs of a foreign listing
3. We don't have to worry about the legalistic and often corrupt dealings within the USA. Their lawyers are always looking for a scam way to make a buck off foreign companies.
4. Clinical trials are very difficult to speed up, I don't care if it takes another year.
All good.
 
Knobby22 said:
Australian shareholders are better off
1. We don't get diluted
2. We don't wear the costs of a foreign listing
3. We don't have .. legalistic and often corrupt dealings within the USA.
4. Clinical trials are very difficult to speed up, I don't care if it takes another year.
Click to expand...
5. we may receive a takeover offer
 
and has hit $20

Q2 2024 Financial Performance and Guidance Upgrade​

The Company reports unaudited total revenue of approximately US$124M
(AU$189M) primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®. This represents an increase of 55% on the prior corresponding quarter (Q2 2023: US$80M or AU$120M) and an increase of 8% on the previous quarter (Q1 2024: US$115M or AU$175M). Revenue generated from sales of Illuccix® in the United States was approximately US$121M (AU$184M, Q2 2023: US$78M or AU$116M).

On the basis of these results, the Company has upgraded revenue guidance for FY2024 which is now expected to be in the range of US$490M to US$510M (AU$745M to AU$776M at current exchange rates). This represents an approximate increase of 48% to 54% on 2023 revenue. Prior guidance was ranged at US$445M to US$465M2(AU$675M to AU$705M).
 

Similar threads

System
CU6 - Clarity Pharmaceuticals
2
Replies
28
Views
6K
Ferret
Ferret
O
INEX Pharmaceuticals: Great licensing agreement with Hana Biosciences
Replies
3
Views
5K
ollinbg
O
Top